MTOR and glomerulosclerosis: Inhibition of mTOR by rapamycin in the setting of adaptive hypertrophy results in proteinuria and glomerulosclerosis, whereas inhibition of mTOR in the setting of maladaptive hypertrophy could be of therapeutic benefit [586].